Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide

Recent evidence suggests that bacterial lipopolysaccharide binds to serum lipoproteins in vitro and in vivo and that lipopolysaccharide in the form that is bound to lipoprotein is less biologically active in several experimental models. In order to study the mechanism of this apparent detoxification, we compared the ability of free and lipoprotein-bound lipopolysaccharide from Escherichia coli O18 to stimulate interleukin-1, interleukin-6, and tumor necrosis factor from elicited murine peritoneal macrophages and circulating human monocytes. Lipopolysaccharide bound to lipoprotein was 20- to 1,000-fold less active than the unbound form in inducing the release of each cytokine. We also studied the binding of each form of lipopolysaccharide to the macrophage surface. Lipopolysaccharide complexed to lipoprotein was unable to compete for the binding of radiolabeled heterologous lipopolysaccharide to murine macrophages, and radiolabeled lipopolysaccharide-lipoprotein complexes bound poorly compared with molar equivalents of free lipopolysaccharide. Our experiments suggest that in the process of binding to lipoproteins, lipopolysaccharide may be rendered less toxic through a mechanism of decreased ability to induce monocytes and macrophages to release cytokines, perhaps because of an altered interaction at the cell surface.

[1]  H. Northoff,et al.  Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins , 1989, Infection and immunity.

[2]  J. Cavaillon,et al.  Dissociation of cell-associated interleukin-1 (IL-1) and IL-1 release induced by lipopolysaccharide and lipid A , 1989, Infection and immunity.

[3]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[4]  D. Morrison,et al.  The physical-chemical characterization and biologic activity of serum released lipopolysaccharides. , 1988, Journal of immunology.

[5]  L. Chedid,et al.  Control of endotoxin activity and interleukin-1 production through regulation of lipopolysaccharide-lipoprotein binding by a macrophage factor , 1988, Infection and immunity.

[6]  W. Koff,et al.  Interleukin 1 release by human monocytes treated with liposome-encapsulated lipopolysaccharide. , 1987, Journal of immunology.

[7]  J. Cavaillon,et al.  Inhibition by gangliosides of the specific binding of lipopolysaccharide (LPS) to human monocytes prevents LPS-induced interleukin-1 production. , 1987, Cellular immunology.

[8]  C. Dinarello,et al.  Role of interleukin-1 in augmenting serum neutralization of bacterial lipopolysaccharide , 1987, Journal of clinical microbiology.

[9]  C. Uyttenhove,et al.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. S. Warren,et al.  Neutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum. , 1986, The Journal of infectious diseases.

[11]  J. Cavaillon,et al.  Inability of pyrogenic, purified Bordetella pertussis lipid A to induce interleukin-1 release by human monocytes , 1986, Infection and immunity.

[12]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[13]  R. Ulevitch,et al.  Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum , 1986, The Journal of experimental medicine.

[14]  B. Beutler,et al.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 , 1986, The Journal of experimental medicine.

[15]  B. Beutler,et al.  Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. , 1985, Journal of immunology.

[16]  D. E. Brown,et al.  Ganglioside modulation of lipopolysaccharide-initiated complement activation. , 1985, Molecular immunology.

[17]  R. Ulevitch,et al.  Control of lipopolysaccharide-high-density lipoprotein interactions by an acute-phase reactant in human serum , 1985, Infection and immunity.

[18]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[19]  J. Cavaillon,et al.  Specific binding of endotoxin to human monocytes and mouse macrophages: serum requirement. , 1985, Cellular immunology.

[20]  H. S. Warren,et al.  Turbidimetric method for quantifying serum inhibition of Limulus amoebocyte lysate , 1985, Journal of clinical microbiology.

[21]  J. Cavaillon,et al.  Interleukin 1 secretion by human monocytes stimulated by the isolated polysaccharide region of the Bordetella pertussis endotoxin. , 1984, Molecular immunology.

[22]  R. Ulevitch,et al.  Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). , 1983, Journal of immunology.

[23]  J. Lipton,et al.  Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. , 1982, The Journal of clinical investigation.

[24]  R. Ulevitch,et al.  INTERACTIONS OF BACTERIAL LIPOPOLYSACCHARIDE WITH ACUTE PHASE RABBIT SERUM , 1982 .

[25]  R. Munford,et al.  Binding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins , 1981, Infection and immunity.

[26]  R. Ulevitch,et al.  In vivo interaction of bacterial lipopolysaccharide (LPS) with rabbit platelets: modulation by C3 and high density lipoproteins. , 1981, Journal of immunology.

[27]  R. Ulevitch,et al.  New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. , 1979, The Journal of clinical investigation.

[28]  R. Ulevitch,et al.  The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. , 1978, The Journal of clinical investigation.

[29]  R. Jordon,et al.  Rapid identification of monocytes in a mixed mononuclear cell preparation. , 1977, Journal of immunological methods.

[30]  E. Milner,et al.  Preparation and properties of a national reference endotoxin , 1976, Journal of clinical microbiology.

[31]  J. Watson,et al.  Genetic control of responses to bacterial lipopolysaccharides in mice. II. A gene that influences a membrane component involved in the activation of bone marrow-derived lymphocytes by lipipolysaccharides. , 1975, Journal of immunology.

[32]  R. Skarnes,et al.  Host resistance to bacterial endotoxemia: mechanisms in endotoxin-tolerant animals. , 1973, The Journal of infectious diseases.

[33]  L. Rothfield,et al.  Reconstitution of a functional membrane enzyme system in a monomolecular film. I. Formation of a mixed monolayer of lipopolysaccharide and phospholipid. , 1970, Journal of Molecular Biology.

[34]  L. Rothfield,et al.  Reconstitution of a functional membrane enzyme system in a monomolecular film. II. Formation of a functional ternary film of lipopolysaccharide, phospholipid and transferase enzyme. , 1970, Journal of molecular biology.

[35]  C. Galanos,et al.  The metabolic fate of endotoxins. , 1988, Progress in clinical and biological research.